Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

ClinicalTrials.gov ID: NCT00988247

Public ClinicalTrials.gov record NCT00988247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approved for the treatment of asthma. BDP-HFA should be safe and effective as a "dry" nasal aerosol which may be preferred by some patients.

Study identification

NCT ID
NCT00988247
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
529 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2009
Primary completion
Feb 27, 2011
Completion
Feb 27, 2011
Last update posted
Dec 2, 2021

2009 – 2011

United States locations

U.S. sites
34
U.S. states
19
U.S. cities
34
Facility City State ZIP Site status
Teva Clinical Sudy Site Oxford Alabama 36203
Teva Clinical Study Site Encinitas California 92024
Teva Clinical Study Site Huntington Beach California 92647
Teva Clinical Study Site San Diego California 92120
Teva Clinical Study Site Stockton California 95207
Teva Clinical Study Site Colorado Springs Colorado 80907
Teva Clinical Study Site Atlanta Georgia 30342
Teva Clinical Study Site Stockbridge Georgia 30281
Teva Clinical Study Site Normal Illinois 61761
Teva Clinical Study Site Lenexa Kansas 66215
Teva Clinical Study Site Overland Park Kansas 66210
Teva Clinical Study Site Metairie Louisiana 70006
Teva Clinical Study Site Wheaton Maryland 20902
Teva Clinical Study Site Ypsilanti Michigan 48197
Teva Clinical Study Site Minneapolis Minnesota 55402
Teva Clinical Study Site Plymouth Minnesota 55441
Teva Clinical Study Site Bozeman Montana 59718
Teva Clinical Study Site North Syracuse New York 13212
Teva Clinical Study Site Rochester New York 14618
Teva Clinical Study Site Rockville Centre New York 11570
Teva Clinical Study Site High Point North Carolina 27262
Teva Clinical Study Site Cincinnati Ohio 45231
Teva Clinical Study Site Sylvania Ohio 43560
Teva Clinical Study Site Eugene Oregon 97401
Teva Clinical Study Site Bethlehem Pennsylvania 18020
Teva Clinical Study Site Collegeville Pennsylvania 19426
Teva Clinical Study Site Dallas Texas 75231
Teva Clinical Study Site El Paso Texas 79903
Teva Clinical Study Site Houston Texas 77054
Teva Clinical Study Site Kerrville Texas 78028
Teva Clinical Study Site San Antonio Texas 78229
Teva Clinical Study Site Vancouver Washington 98664
Teva Clinical Study Site Greenfield Wisconsin 53228
Teva Clinical Study Site West Allis Wisconsin 53227

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00988247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00988247 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →